



सत्यमेव जयते

Government of India  
Central Drugs Standard Control Organisation(Headquarter)  
(Directorate General of Health Services)  
FDA Bhavan, ITO, Kotla Road  
New Delhi - 110002 (Delhi)  
Phone No.: 91-11-23216367  
Fax No.: 91-11-23236973  
E-Mail: dci@nic.in

File No. BIO/CT/23/000144

Dated 13-05-2024

To

M/s Zydus Lifesciences Limited,  
Plot Survey No. 23, 25/P,37, 4/P, 42 to 47,  
Sarkhej-Bavla, N.H. No-8A, Opposite Ramdev Masala,  
Village Changodar, Tal. Sanand, Ahmedabad (India)-382213

Subject: Application for grant of permission to conduct Phase-1/2 clinical trial titled "A phase 1/2, prospective, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending doses of intravenously administered ZRC-NB-3224 in healthy adult participants and in patients with paroxysmal nocturnal hemoglobinuria" vide Protocol No. ZAP 1001; Version 01 dated 7th December 2023 with indigenously developed ZRC-NB-3224 Product - regarding

Ref. No.: Your Application No. BIO/CT04/FF/2023/40890 dated 08-DEC-2023

Sir,

With reference to your application No.BIO/CT04/FF/2023/40890 dated 08-DEC-2023, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Firm should submit the results of Phase I study (Single ascending dose study) of the proposed trial to CDSCO for further evaluation by the committee before proceeding to Phase II study (Multiple ascending dose study) of the proposed trial.
- (II) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8.
- (III) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (IV) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (V) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (VI) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial.

- (VII) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (VIII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (IX) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal.
- (X) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination.
- (XI) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI.
- (XII) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter.
- (XIII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter.
- (XIV) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial.
- (XV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority.
- (XVI) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial.
- (XVII) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVIII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

**RAJEEV SINGH**  
**RAGHUVANSHI**

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL  
ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,  
2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c27690  
41015a06564fe67f54b765db1cb,  
postalCode=600034, st=TAMIL NADU,  
serialNumber=657F5E47D940985D8F03BDC902DOE1  
FE73CFA12A1A126EA94FA5701124A19013,  
cn=RAJEEV SINGH RAGHUVANSHI  
Date: 2024.05.13 16:26:49 +05'30'

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)  
Central Licensing Authority

## FORM CT-06

(See rules 22, 25, 26, 29 and 30)

### PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s Zydus Lifesciences Limited, Plot Survey No. 23, 25/P,37, 4/P, 42 to 47, Sarkhej-Bavla, N.H. No-8A, Opposite Ramdev Masala, Village Changodr, Tal. Sanand, Ahmedabad (India) – 382213 to conduct Phase-1/2 clinical trial titled “A phase 1/2, prospective, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending doses of intravenously administered ZRC-NB-3224 in healthy adult participants and in patients with paroxysmal nocturnal hemoglobinuria” vide Protocol No. ZAP 1001; Version 01 dated 7th December 2023 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi  
Date: 13-May-2024

**RAJEEV SINGH  
RAGHUVANSHI**

Digitally signed by RAJEEV SINGH RAGHUVANSHI  
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL  
ORGANIZATION, ou=RAJEEV SINGH RAGHUVANSHI,  
2.5.4.20=80c626a23e4eafbe8a239774cdeb03c27690  
41015a06564fe67f54b765db1cb,  
postalCode=600034, st=TAMIL NADU,  
serialNumber=657F5E47D940985D8F038DC902D0E1  
FE73CFA12A1A126EA94FA5701124A19013,  
cn=RAJEEV SINGH RAGHUVANSHI  
Date: 2024.05.13 16:27:12 +05'30'

(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)  
Central Licensing Authority

CDSCO

CDSCO

MINISTRY OF HEALTH, GOVERNMENT OF INDIA

सत्यमेव जयते

**Annexure:****Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	ZRC-NB-3224 (humanized monoclonal antibody (IgG4 $\kappa$ isotype))			
Dosage form:	Powder for concentrate for solution for infusion			
Therapeutic Class	Complement blocker			
Composition:	Each vial contains:			
	<b>Name of Ingredients</b>	<b>Function</b>	<b>Quantity per vial</b>	
			<b>300 mg strength</b>	<b>750 mg strength</b>
	ZRC-NB-3224 monoclonal antibody IH	Anti-properdin	300 mg	750 mg
	L-Histidine Ph.Eur., USP	Buffer component	7.8 mg	19.5 mg
	L-Histidine-HCl Ph.Eur., BP	Buffer component	10.4 mg	26 mg
	L-Arginine-HCl Ph.Eur., USP	Stabilizer	50 mg	125 mg
	$\alpha, \alpha$ -Trehalose dehydrate Ph.Eur., NF	Lyoprotectant	500 mg	1250 mg
Polysorbate 80 IP, Ph.Eur., USP/NF	Surfactant	2 mg	5 mg	
	Bulk fill volume	11.5 mL (approx.)	29 mL (approx.)	
Indication:	For the treatment of paroxysmal nocturnal hemoglobinuria (PNH).			

**Details of clinical trial site(s):**

S.No.	Name and Address of Clinical Trial Site(s)	Ethics Committee Details	Name of Principal Investigator
1.	Zydus Lifesciences Ltd., Zydus Research Centre, Survey No. 396/403, Opp. Sarvotam Hotel, Nr. Nova Petrochemicals, Sarkhej- Bavla N.H. N. 8A, Moraiya, Ahmedabad-382210 Gujarat, India	Riddhi Medical Nursing Home IEC Riddhi Medical Nursing Home A/101 Jalaram Plaza, Jawahar Chowk, Maninagar, Ahmedabad, Gujarat - 380008 India EC Reg. No.: ECR/886/Inst/GJ/2016/RR-19	Dr. Kevin Kumar Kansagra